Kazia Therapeutics announced that its drug paxalisib achieved an 83% objective response rate in six evaluable patients with Stage IV triple-negative breast cancer, including one complete response and four partial responses. All patients showed reductions in metastasis-associated circulating tumor cell clusters and improvements in immune function, with no serious treatment-related adverse events reported. These promising results suggest paxalisib may overcome treatment resistance by restoring immune activity and reducing cancer spread. The ongoing Phase 1b trial combining paxalisib with pembrolizumab and chemotherapy is expected to complete enrollment by July 2027, with updates planned through 2026 and 2027.
Best Buy reported a strong fiscal Q2 2027 with revenue up 3.6% to $9.78 billion and comparable sales rising 4.1%, surpassing expectations. Adjusted diluted EPS increased 15% to $1.47, helped partly by $34 million in tariff refunds. Following these re...
BP, a major global energy company, is actively managing its portfolio by potentially selling oil and gas assets in Egypt to Energean and investing in new projects like a Halliburton contract in Brazil's offshore field. This strategic move aims to enh...
Blockstream has introduced a Bitcoin Improvement Proposal (BIP) called SHRINCS, a post-quantum signature scheme designed to protect Bitcoin from potential quantum computing threats. SHRINCS is already tested on Blockstream’s Liquid sidechain but pres...
Evernorth Holdings received SEC approval for its Form S-4 registration, enabling its merger with Armada Acquisition Corp. II and a Nasdaq listing under the ticker XRPN. The merger is expected to raise over $1 billion, making Evernorth the largest pub...
Radiant World, a Singapore-based iron ore trading firm claiming $9.6 billion in revenue, is losing key partners after allegations of invalid invoices surfaced. Major commodity traders like Vitol, Cargill, and Glencore stopped business with Radiant, t...
